Modified insulin used to treat type 1 and 2 diabetes. Approved in US in 2000, 76th most prescribed medication in 2022. Works by increasing glucose uptake and decreasing liver glucose production. Manufactured using yeast with insulin aspart gene
Intermediate-acting insulin used to control blood sugar in diabetes. Onset in 90 minutes, lasts up to 24 hours. Cloudy appearance with peak effect at 6-8 hours. Available in human and pig insulin versions
Degludec contains threonine removed from B chain and fatty diacid attached to lysine. Forms stable depot in subcutaneous tissue with predictable dissociation. Achieves peak plasma concentration after 10-12 hours. Has half-life of 17-25 hours, twice that of insulin glargine
Contains 70% insulin degludec and 30% insulin aspart for diabetes treatment. Used for patients aged 6 years and older. Designed for use with Novo Nordisk insulin delivery systems
Levemir is a long-acting insulin analogue for diabetes treatment. Available in Penfill, FlexPen, InnoLet and FlexTouch pre-filled pens. Contains 100 units insulin detemir per ml solution. Used for adults, adolescents and children aged 1 year and above
Regular insulin available in 100 and 500 units/mL concentrations. Total daily insulin requirement is 0.5-1 unit/kg/day. U-100 insulin can be administered IV or subcutaneously. U-500 insulin only for subcutaneous administration